Compare · AIMD vs LLY
AIMD vs LLY
Side-by-side comparison of Ainos Inc. (AIMD) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIMD and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.05T, about 85363.9x AIMD ($12.3M).
- Over the past year, AIMD is down 56.3% and LLY is up 49.0% - LLY leads by 105.3 points.
- LLY has been more active in the news (7 items in the past 4 weeks vs 1 for AIMD).
- LLY has more recent analyst coverage (25 ratings vs 0 for AIMD).
- Company
- Ainos Inc.
- Eli Lilly and Company
- Price
- $1.48-4.52%
- $1114.83-0.70%
- Market cap
- $12.3M
- $1.05T
- 1M return
- +1.37%
- -8.62%
- 1Y return
- -56.34%
- +48.98%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 7
- Recent ratings
- 0
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest AIMD
- Ainos Secures Three Japanese Robotics Patents, Advancing Chemical Perception for the Physical AI Era
- Ainos Launches Atmosphere Engine, Extending Physical AI from Environmental Sensing to Active Environmental Management
- Ainos Unveils Next-Generation AI Nose, Advancing the Infrastructure for Chemical Intelligence
- Ainos Surpasses 878 Million Real-World Data Points, Up 43% in 23 Days as 1,400-System AI Nose Semiconductor Deployment Advances
- Ainos to Showcase Environmental Intelligence for Physical AI at SEMICON Taiwan 2026
- VASRO Research Highlights Ainos' Progress in Scaling Smell AI Commercialization and Compounding Its Smell ID Dataset
- Zacks Small-Cap Research Covers Ainos' AI Nose Platform and Expansion of Smell AI Applications
- Ainos Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Ainos Reports Second Quarter 2026 Results and Highlights Continued AI Nose Execution Across Industrial, Healthcare Infrastructure and Robotics Markets
- SEC Form 10-Q filed by Ainos Inc.
Latest LLY
- EVP, Global Quality Seymour Melissa gifted 29 shares, decreasing direct ownership by 3% to 1,038 units (SEC Form 4)
- Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
- Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
- FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)